170 related articles for article (PubMed ID: 22122585)
1. Grand challenges in modulating the immune response with RNAi nanomedicines.
Goldsmith M; Mizrahy S; Peer D
Nanomedicine (Lond); 2011 Dec; 6(10):1771-85. PubMed ID: 22122585
[TBL] [Abstract][Full Text] [Related]
2. RNAi nanomedicines: challenges and opportunities within the immune system.
Weinstein S; Peer D
Nanotechnology; 2010 Jun; 21(23):232001. PubMed ID: 20463388
[TBL] [Abstract][Full Text] [Related]
3. Overcoming RNAi transduction in leukocytes using targeted and stabilized nanoparticles.
Elfakess R; Peer D
IDrugs; 2010 Sep; 13(9):626-31. PubMed ID: 20799145
[TBL] [Abstract][Full Text] [Related]
4. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs.
Aigner A
J Biotechnol; 2006 Jun; 124(1):12-25. PubMed ID: 16413079
[TBL] [Abstract][Full Text] [Related]
5. A daunting task: manipulating leukocyte function with RNAi.
Peer D
Immunol Rev; 2013 May; 253(1):185-97. PubMed ID: 23550647
[TBL] [Abstract][Full Text] [Related]
6. Induction of therapeutic gene silencing in leukocyte-implicated diseases by targeted and stabilized nanoparticles: a mini-review.
Peer D
J Control Release; 2010 Nov; 148(1):63-68. PubMed ID: 20624432
[TBL] [Abstract][Full Text] [Related]
7. Safety profile of RNAi nanomedicines.
Barros SA; Gollob JA
Adv Drug Deliv Rev; 2012 Dec; 64(15):1730-7. PubMed ID: 22732527
[TBL] [Abstract][Full Text] [Related]
8. RNA interference for therapy in the vascular endothelium.
Kaufmann J; Ahrens K; Santel A
Microvasc Res; 2010 Sep; 80(2):286-93. PubMed ID: 20144624
[TBL] [Abstract][Full Text] [Related]
9. Potential use of RNA interference in cancer therapy.
Phalon C; Rao DD; Nemunaitis J
Expert Rev Mol Med; 2010 Aug; 12():e26. PubMed ID: 20716384
[TBL] [Abstract][Full Text] [Related]
10. RNA interference: new mechanisms for targeted treatment?
Woessmann W; Damm-Welk C; Fuchs U; Borkhardt A
Rev Clin Exp Hematol; 2003 Sep; 7(3):270-91. PubMed ID: 15024970
[TBL] [Abstract][Full Text] [Related]
11. Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies.
Weinstein S; Toker IA; Emmanuel R; Ramishetti S; Hazan-Halevy I; Rosenblum D; Goldsmith M; Abraham A; Benjamini O; Bairey O; Raanani P; Nagler A; Lieberman J; Peer D
Proc Natl Acad Sci U S A; 2016 Jan; 113(1):E16-22. PubMed ID: 26699502
[TBL] [Abstract][Full Text] [Related]
12. RNAi-based nanomedicines for targeted personalized therapy.
Daka A; Peer D
Adv Drug Deliv Rev; 2012 Oct; 64(13):1508-21. PubMed ID: 22975009
[TBL] [Abstract][Full Text] [Related]
13. Circular RNA interference effector molecules (WO10084371).
Lundin P; Moreno PM; Smith CI; Andaloussi SE
Expert Opin Ther Pat; 2011 Jan; 21(1):115-9. PubMed ID: 21110768
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of RNA interference against cancer.
Takeshita F; Ochiya T
Cancer Sci; 2006 Aug; 97(8):689-96. PubMed ID: 16863503
[TBL] [Abstract][Full Text] [Related]
15. Prospects of RNA interference therapy for cancer.
Pai SI; Lin YY; Macaes B; Meneshian A; Hung CF; Wu TC
Gene Ther; 2006 Mar; 13(6):464-77. PubMed ID: 16341059
[TBL] [Abstract][Full Text] [Related]
16. Nonviral in vivo delivery of therapeutic small interfering RNAs.
Aigner A
Curr Opin Mol Ther; 2007 Aug; 9(4):345-52. PubMed ID: 17694447
[TBL] [Abstract][Full Text] [Related]
17. siRNAs: their potential as therapeutic agents--Part II. Methods of delivery.
Singh SK; Hajeri PB
Drug Discov Today; 2009 Sep; 14(17-18):859-65. PubMed ID: 19540929
[TBL] [Abstract][Full Text] [Related]
18. Exploring cell type-specific internalizing antibodies for targeted delivery of siRNA.
Liu B
Brief Funct Genomic Proteomic; 2007 Jun; 6(2):112-9. PubMed ID: 17670766
[TBL] [Abstract][Full Text] [Related]
19. Receptor-targeted liposome-peptide nanocomplexes for siRNA delivery.
Tagalakis AD; He L; Saraiva L; Gustafsson KT; Hart SL
Biomaterials; 2011 Sep; 32(26):6302-15. PubMed ID: 21624650
[TBL] [Abstract][Full Text] [Related]
20. RNA interference: a novel and physiologic mechanism of gene silencing with great therapeutic potential.
Calderón AJ; Lavergne JA
P R Health Sci J; 2005 Mar; 24(1):27-33. PubMed ID: 15895874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
